Page 8 - Houng Kim News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Celltrion Healthcare erhält positive Stellungnahme des CHMP der EU für das Adalimumab-Biosimilar CT-P17
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Celltrion Healthcare erhält positive Stellungnahme des CHMP der EU für das Adalimumab-Biosimilar CT-P17
boerse-social.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boerse-social.com Daily Mail and Mail on Sunday newspapers.
Celltrion Healthcare receives EU CHMP positive opinion for biosimilar adalimumab, CT-P17
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of CT-P17 (adalimumab biosimilar) for the treatment of multiple chronic inflammatory diseases
The positive opinion is based on Phase I/III study data investigating the equivalence of CT-P17 to reference adalimumab in terms of efficacy, pharmacokinetics (PK) and overall safety
If approved, CT-P17 would be the first adalimumab biosimilar with high concentration (100mg/mL) and citrate-free formulation
Celltrion Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorisation of an adalimumab biosimilar candidate referencing Humira